user

A real-world prospective observational multi-national study in adult patients with breast cancer treated with extended adjuvant neratinib: NERLYFE study

被引：0
|
作者：
Harbeck, N. [1 ]
Jegannathen, A. [2 ]
Schmidt, M. [3 ]
Tsalic, M. [4 ]
Baerens, D. -T. [5 ]
Baschar, Y. [6 ]
Davies, M. [7 ]
Abdulkhalek, H. [8 ]
Smakal, M. [9 ]
Beghdad, F. [10 ]
Castagne, C. [10 ]
Zivanov, M. [10 ]
Bartsch, R. [11 ]
机构：
[1] Ludwig Maximilians Univ Munchen, Dept Gynecol & Obstet, Ctr Comprehens Canc, Breast Ctr, Munich, Germany
[2] Univ Hosp North Midlands NHS Trust, Dept Oncol, Stoke On Trent, Staffs, England
[3] Johannes Gutenberg Univ Mainz, Dept Obstet & Gynecol, Mainz, Germany
[4] Univ Hosp Birmingham NHS Fdn Trust, Birmingham, W Midlands, England
[5] Gynako Onkolog Praxis, Ilsede, Germany
[6] Brustzentrum Stadt Kliniken Monchengladbach, Monchengladbach, Germany
[7] Singleton Hosp, Swansea, W Glam, Wales
[8] Western Hlth Social Care Trust, Med Oncol Dept, Londonderry, North Ireland
[9] Nemocnice Horovice, Onkol Oddeleni, Horovice, Czech Republic
[10] Pierre Fabre, Boulogne, France
[11] Med Univ Vienna, Div Oncol, Dept Med 1, Vienna, Austria
来源：
BREAST | 2023年 / 68卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P009
引用
收藏
页码：S18 / S19
页数：2
相关论文
共 50 条
  • [1] A real-world prospective observational multi-national study in adult patients with breast cancer treated with extended adjuvant neratinib: NERLYFE study
    Bartsch, R.
    Baerens, D. -T
    Jegannathen, A.
    Youssef, B.
    Abdulkhalek, H.
    Davies, M.
    Smakal, M.
    Zimovjanova, M.
    Schmidt, M.
    Beghdad, F.
    Castagne, C.
    Zivanov, M.
    Harbeck, N.
    ONCOLOGY RESEARCH AND TREATMENT, 2023, 46 : 167 - 167
  • [2] (Trial in progress) A real-life prospective, observational, post-authorisation safety study in adult breast cancer patients treated with neratinib in extended adjuvant in Europe: the NERLYFE study
    Valenti, R.
    Plantet, C.
    Tadmouri, A.
    BREAST, 2021, 56 : S20 - S20
  • [3] Interim analysis of ELEANOR (n=200): a multi-national, prospective, non-interventional study (NIS) among patients with HER2+and HR+ early breast cancer (eBC) treated with extended adjuvant neratinib
    Bartsch, R.
    Harbeck, N.
    Wrobel, D.
    Zaiss, M.
    Terhaag, J.
    Guth, D.
    Distelrath, A.
    Wuerstlein, R.
    Zahn, M. -O.
    Lueftner, D.
    Schwitter, M.
    Balic, M.
    Jackisch, C.
    Mueller, V.
    Rinnerthaler, G.
    Schmidt, M.
    Zaman, K.
    Schinkoethe, T.
    Gorray, M.
    Breitenstein, U.
    BREAST, 2023, 68 : S20 - S21
  • [4] Interim analysis (n=200) of ELEANOR: a multi-national, prospective, non-interventional study among patients with HER2+and HR+ early breast cancer (eBC) treated with extended adjuvant neratinib in the clinical routine
    Bartsch, R.
    Harbeck, N.
    Wrobel, D.
    Zaiss, M.
    Terhaag, J.
    Guth, D.
    Distelrath, A.
    Wuerstlein, R.
    Zahn, M. -O
    Lueftner, D.
    Schwitter, M.
    Balic, M.
    Jackisch, C.
    Mueller, V
    Rinnerthaler, G.
    Schmidt, M.
    Zaman, K.
    Schinkoethe, T.
    Vannier, C.
    Breitenstein, U.
    ONCOLOGY RESEARCH AND TREATMENT, 2023, 46 : 170 - 171
  • [5] Interim analysis (n=150) of the multi-national, prospective, non-interventional ELEANOR study observing real-life extended adjuvant treatment with neratinib in patients with HER2+/ HR+ early breast cancer (eBC)
    Lueftner, Diana
    Bartsch, Rupert
    Breitenstein, Urs
    Balic, Marija
    Jackisch, Christian
    Mueler, Volkmar
    Rinnerthaler, Gabriel
    Schmidt, Marcus
    Schwitter, Michael
    Zaman, Khalil
    Wrobel, Denise
    Guth, Dagmar
    Terhaag, Juergen
    Zaiss, Matthias
    Distelrath, Andrea
    Lorenz, Andreas
    Schinkoethe, Timo
    Harbeck, Nadia
    ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 3) : 20 - 21
  • [6] Interim analysis (n=150) of the multi-national, prospective, non-interventional ELEANOR study observing real-life extended adjuvant treatment with neratinib in patients with HER2+/ HR+ early breast cancer (eBC)
    Harbeck, N.
    Wrobel, D.
    Zaiss, M.
    Guth, D.
    Distelrath, A.
    Terhaag, J.
    Lorenz, A.
    Bartsch, R.
    Breitenstein, U.
    Schwitter, M.
    Balic, M.
    Jackisch, C.
    Mueller, V.
    Rinnerthaler, G.
    Schmidt, M.
    Zaman, K.
    Schinkoethe, T.
    Lueftner, D.
    ANNALS OF ONCOLOGY, 2022, 33 : S157 - S157
  • [7] An Emollient PLUS Balm Is Useful for the Management of Xerosis in Patients Treated for Cancer: A Real-World, Prospective, Observational, Multicenter Study
    Vendrely, Veronique
    Mayor-Ibarguren, Ander
    Stennevin, Aline
    Ortiz-Brugues, Ariadna
    DERMATOLOGY AND THERAPY, 2022, 12 (03) : 683 - 699
  • [8] An Emollient PLUS Balm Is Useful for the Management of Xerosis in Patients Treated for Cancer: A Real-World, Prospective, Observational, Multicenter Study
    Véronique Vendrely
    Ander Mayor-Ibarguren
    Aline Stennevin
    Ariadna Ortiz-Brugués
    Dermatology and Therapy, 2022, 12 : 683 - 699
  • [9] A real-world prospective observational study of eptinezumab in Asian patients with migraine
    Zhao, Yi Jing
    Ong, Jonathan Jia Yuan
    Sonu, Sumit Kumar
    Dang, Jiaojiao
    Ng, Chai Ching
    Herr, Keira Joann
    Bose, Rohini
    Jion, Yasmin Idu
    HEADACHE, 2024, 64 (07): : 810 - 824
  • [10] XANTUS: a real-world, prospective, observational study of patients treated with rivaroxaban for stroke prevention in atrial fibrillation
    Camm, A. John
    Amarenco, Pierre
    Haas, Sylvia
    Hess, Susanne
    Kirchhof, Paulus
    Kuhls, Silvia
    van Eickels, Martin
    Turpie, Alexander G. G.
    EUROPEAN HEART JOURNAL, 2016, 37 (14) : 1145 - 1153
12345